Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

Clinical Infectious Diseases

Volumn 39, Issue 7, 2004, Pages 1024-1029

  Gil, Paloma ^a   De Górgolas, Miguel ^a,d   Estrada, Vicente ^b   Arranz, Alberto ^c   Rivas, Pablo ^a   Yera, Carmen ^a   García, Rosa ^a   Granizo, Juan J ^a   Fernández Guerrero, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY PAIN; LIVER TOXICITY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; VIRUS LOAD; WITHDRAWAL SYNDROME;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 4744353225     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/423385     Document Type: Article

References (28)

1. Palella FJ, Delaney KM, Norman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The HIV Outpatient Investigators. N Engl J Med 1998; 338:853-60.
2. Temesgen Z, Wright AJ. Antiretrovirals. Mayo Clin Proc 1999; 74: 1284-301.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
4. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14:807-12.
5. Moyle G. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 2001; 61:19-26.
6. Raffi F, Bonnet B, Ferré V, et al. Substitution of a normucleoside reverse-transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000; 31:1274-8.
7. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. J Acquir Immune Defic Syndr 2001; 27:229-36.
8. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34:504-10.
9. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16:1383-9.
10. Martfnez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-10.
11. Van der Valk M, Kastelein JJP, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. The Atlantic Study team. AIDS 2001; 15: 2407-14.
12. Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther 2000; 5:267-72.
13. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445.
14. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998; 27: 1321-2.
15. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36:1598-613.
16. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drugs users. Clin Infect Dis 2001; 33:1595-7.
17. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infections: a review. Mt Sinai J Med 2000; 67:429-36.
18. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med 2002; 137:146-7.
19. Fernández-Guerrero ML, Becares J, Górgolas M, García Delgado R. Nevirapine induced acute hepatitis [abstract I-209]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:312.
20. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-8.
21. González de Requena D, Núñez M, Jiménez- Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-1.
22. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine cohort, 1997-1999. Clin Infect Dis 2002; 35:1231-7.
23. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic clinical fat redistribution. AIDS Read 2000; 10:479-85.
24. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. The AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339:1261-8.
25. Bucher HC, Kofier A, Nüesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomised controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1 infected patients. AIDS 2003; 17:2451-9.
26. Serious adverse events attributed to nevirapine regimens for postex-posure prophylaxis after HIV exposures worldwide-1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49:1153-6.
27. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
28. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/. Accessed 2 February 2004.